Introduction
HIV infection is highly prevalent in injection drug users (IDU) with upwards of 40 % in various regions globally (Beyrer et al. 2010) . While IDU was recognized early in the history of HIVas a potential means of transmitting the disease by sharing needles with blood remnants, IDU has also been observed to correlate with a more severe HIV pathogenesis than non-users including a much faster development of AIDS and higher rates of neurocognitive deficiencies (Donahoe and Vlahov 1998; Kapadia et al. 2005) . The mechanism for this is currently unknown, however it likely occurs via a combination of the ability of the drugs to modulate systemic changes in the patient along with decreased access to adequate healthcare (Wolfe et al. 2010) .
Clinically, it is nearly impossible to delineate how IDU may enhance HIV due to poly-drug use which is estimated to occur in over 70 % of IDU patients (Kedia et al. 2007 ). Opioids, the most common IDU agent in HIV cases, have been shown in mouse models to have drastic systemic effects including the immune system. As a consequence, there are significant interactions between HIV and opioid use in the immune compartment. Understanding these interactions is important, especially at the early stages of disease, in order to develop interventions and prevent the severity of HIV pathogenesis observed in IDU-using infected patients.
Early stages of pathogenesis in HIV infection has been difficult to study in clinical populations since the disease does not make itself obvious until years later when opportunistic infections develop. Nonhuman primates infected with Simian Immunodeficiency Virus (SIV) have been an invaluable tool to overcome this limitation, especially since there are both pathogenic and nonpathogenic species which allows for differences between the two to be mapped (Gordon et al. 2007; Pandrea et al. 2007 ). Initial stages of HIV pathogenesis are now strongly believed to be reliant on microbial translocation from the gut which drives the systemic inflammation needed for HIV/SIV (Brenchley et al. 2006; Nazli et al. 2010 ). Despite these findings, studies of mechanisms in nonhuman primates, as in humans, are still very restricted by the lack of genetic tools and increased cost compared to small animal models like mice.
Developing HIV models for mice has been limited by the host specificity of HIV. Most infectious models have focused on "humanizing" the mice either by creating transgenic mice with human HIV co-receptors or generating chimeric mice with human immune cell grafts (Denton and Garcia 2009; Zhang and Su 2012) . The latter method has shown a remarkable ability to recapitulate HIV pathogenesis in the human immune cells within a mouse (Zhang and Su 2012) . However, studies using chimeric mice cannot adequately make conclusions about physiological effects of HIV infection on nonimmune cells, such as neurons or epithelial cells, because the interactions between human and mouse cells are likely not conserved. Humanized mice are also susceptible to Graft Versus Host Disease, which can further complicate interpretation of results (Shultz et al. 2012) .
For this reason, Potash et al. created the EcoHIV model, which is a genetically modified HIV virus which uses murine leukemia virus gp80 for cell entry in place of gp120 from HIV-1 (Potash et al. 2005) . While previous studies from this group characterized the brain compartment in response to infection (Kelschenbach et al. 2011; He et al. 2014) , the hypothesis for this study was that EcoHIV would recapitulate early consequences of HIV-1 at the systemic level, such as bacterial translocation, and inquired whether combination of infection with opiates would worsen these symptoms.
Materials and Methods

Mice
All studies using mice were approved by the University of Minnesota Animal Care and Use Committee and were conducted in full compliance with NIH guidelines. Male or female C57Bl/6 and BALB/c mice were purchased from the Jackson Laboratory, while Mu Opioid Receptor Knock Out (MORKO) and Toll-Like Receptor 4 Knock Out (TLR4KO) mice were bred in house. All animals were between 10 and 16 weeks of age at the beginning of each experiment.
Morphine Treatment
Mice were implanted with either a placebo or 25 mg slowrelease morphine pellet at 24 h prior to infection with EcoHIV.
Pellets were generously provided by NIH/NIDA. For long term experiments (>7 days), mice were implanted with either 25 mg or 75 mg morphine pellets using a protocol that would increase released morphine every 7 days to avoid tolerance. Escalating doses in the order used were 1× 25 mg, 1× 75 mg, 2× 25 mg, and 2× 75 mg based on a study that showed 2× 25 mg morphine pellets resulted in higher morphine release than 1× 75 mg pellet, likely due to increased surface area with having two pellets (Dighe et al. 2009 ). The first dose given (implant at day 0, exposed 0-7 days) was 25mg slow-release morphine pellet as in short term experiments. The second week (implant at day 7, exposed 7-14 days), mice were pelleted with a 75mg slow-release morphine pellet. The third week (implant at day 14, exposed 14-21 days) mice were pelleted with 2× 25 mg pellets and the final week (implant at day 21, exposed 21-28 days) with 2× 75 mg pellet. At the end of final week, mice were sacrificed and PBS perfused brains was aseptically removed for the quantification of proinflammatory cytokines. In vitro work performed in macrophage cell lines (J774 or RAW) were treated with 1 μM morphine.
EcoHIV Infection
The EcoHIV constructs used in the present work were EcoHIV/NL4-3 which was constructed on the backbone of HIV-1/NL4-3 (Potash) and EcoHIV/NL4-3-GFP which expresses enhanced green fluorescence protein (EGFP) as a marker protein . For brevity, the viruses are called EcoHIV and EcoHIV-GFP. The viruses were propagated in HEK293TN cells as previously described (Potash et al. 2005 ). Mice were injected in the intraperitoneal cavity with 1 mL of either saline or 1×10 6 pg p24 units as measured by p24 ELISA following manufacturer's instructions (ZeptoMetrix Corporation). In vitro work performed in macrophage cell lines (J774 or RAW) were treated with 1×10 3 pg of p24 units per 1×10 6 cells.
Bacterial Translocation
Tissue was harvested and homogenized in sterile PBS with 100 μM cell strainers (BD) following aseptic techniques. Homogenized tissue was then plated on blood agar plates and incubated at 37°C overnight in aerobic conditions. Colonies were counted and normalized for varying protein concentrations in the tissue homogenate.
RNA Isolation and Processing
RNA isolation was performed on homogenized tissue using the Qiagen RNeasy prep and cDNA was generated using the Promega Reverse Transcription System, each according to the manufacturer's protocol. RT-PCR was run and quantified with Sybr Green (Roche) for 40 cycles on an Applied Biosystems 7500 machine. Samples which crossed the threshold above 32 Ct were considered to be non-specific amplification and discarded. Primers are listed in Table 1 .
Histology
Tissues were preserved in 10 % formalin for 24 h and transferred to 70 % ethanol. Samples were then embedded in paraffin, sectioned, and stained using a combination of hematoxylin (nuclei, dark brown), alcian blue (at pH 2.5; goblet cells and mucin, blue), and metanil yellow (nonspecific tissue and connective tissue, yellow) (Edgett 2004) . Stained slides were imaged on a Nikon light microscope at 100×.
FACS
Lamina propria immune cells were collected from small, cecum, or large instestine following a previously published method (Denning et al. 2007 ). Briefly, intestine was washed with HBSS with 5 % FBS and 0.5 M EDTA to remove epithelial cells. Remaining tissue was digested using HBSS with 5 % FBS and 0.4 mg/mL Collagenase (Sigma-Aldrich). Cells were harvested via centrifugation at 500 g and fixed in IC fixation buffer (Ebiosciences) for 20 min on ice and stained using I-A, I-E (AF488, Biolegend), CD4 (PE, BD), CD8 (APC, eBioscience), CD19 (Alexa 700, BD), CD11B (PEcy7, Biolegend), CD11C (PE-cy5, Biolegend), and CD45 (V500, BD) and acquired by a FACS Canto II flow cytometer. Analysis was done using Flowjo software (Treestar Inc).
Phagocytosis
Peritoneal macrophages were harvested by putting 1 mL sterile saline inside the omentum sac and removing to a sterile tube, which were then cultured for 30 min in serum-free media and washed to select for adherent cells. Peritoneal, RAW, or J774 macrophages were cultured with enriched DMEM with and without 1 μM morphine, 10, 000 / well in black 96-well plate or cover slip and incubated with either FITC-dextran or E. coli or S. aureus opsonized particles (1:20, cell:bacteria/ bead ratio) for 30 min. Phagocytosis was stopped by addition of trypan blue, which quenches fluorescence of noninternalized particles. Cells were either analyzed by fluorometry in black 96-well plates after staining with DAPI (D9542 Sigma) or fixed for confocal microscopy on sterile glass cover slips, where they were co-stained with rhodamine phalloidin and Prolong Gold with DAPI (Life Technologies) and imaged by confocal microscopy. Fluorescence was recorded at an excitation of 485 nm and an emission of 520 nm for opsonized particles (FITC) and an excitation of 355 nm and an emission of 460 nm for DAPI. Phagocytosis per cell was quantified as phagocytic Index = FITC/DAPI [both given in relative fluorescence units (RFUs)], indicative of particle fluorescence per cell.
ELISA
Liver and lung homogenate were prepared as described above.
TNFα and IL-6 Ready-Set-Go kits (Ebiosciences) were performed following the manufacturer's instructions.
Statistics
Statistics were analyzed within Prism software (Graphpad Inc) using two-way ANOVA using Bonferroni post-tests to compare each treatment with the others. Groups were considered to be significant if the p-value from the Bonferroni test was p<0.05 or less.
Results
Knowing that EcoHIV can infect CD4+ and macrophages in mice (Potash et al. 2005) , the systemic nature of infection was verified, including whether morphine influences the amplitude of infection. EcoHIV was validated to infect macrophage cell lines in vitro by examining the RNA expression of LTRgag in both J774 and RAW cells. In these cell lines, expression of HIV LTR-gag RNA was observed within EcoHIV infected samples but was undetected in uninfected samples (Fig. 1a) . Infection was also validated in vivo, where again expression levels of LTR-gag RNA were observed in the spleen of infected mice 2, 5, and 7 days post-infection, but not in uninfected (Fig. 1b) . Using EcoHIV which expresses GFP within infected cells (He et al. 2014) , expression of GFP was examined in both F4/80+ macrophages and CD4+ lymphocytes isolated from peritoneal lavage and spleen at 5 days post-infection (Fig. 1c) . Male and female animals manifested similar levels of infection in all cell types with the possible exception of CD4+ peritoneal cells. Peritoneal macrophages were also visually examined using confocal microscopy to verify positive GFP expression in EcoHIV infected animals ( Fig. 1d ). EcoHIV infection was also measured by looking at systemic p24 levels observed in liver ( Fig. 1e) , lung ( Fig. 1f) , and brain ( Fig. 1g ) on day 5, day 10, and day 21 post infection. There was little difference between mice implanted with either placebo or 25 mg pellets of morphine aside from at day 21 in liver ( Fig. 1e) . Together, these results established successful infection of EcoHIV of CD4+ T-cells and macrophages in animals when EcoHIV was administered systemically thus recapitulating observations seen in humans with HIV-1 infections.
Translocation of bacterial products have been shown to play a key role in the early pathogenesis of HIV (Brenchley et al. 2006) . Similarly, sepsis and bacterial translocation have been observed when animals are implanted with morphine pellets (Hilburger et al. 1997; Meng et al. 2013) . In combination, IDU has been shown to increase the translocation induced by HIV (Ancuta et al. 2008) , therefore the question was asked whether bacterial translocation occurs in the EcoHIVinfected animals and will morphine exacerbate the effects. Significant translocation of colony forming units (CFU) occurred at day 2 post infection ( Fig. 2a) but not day 5 post infection ( Fig. 2b) . The highest amount of CFU was observed in the liver when compared to the lung and spleen in animals that were infected with EcoHIV and in morphine treated EcoHIV-infected animals. Liver homogenate was incubated with RAW Blue cells to look for the presence of PAMPs such as LPS from gram-negative bacteria or LTA from grampositive bacteria. Similarly to the CFU translocation observed, day 2 post infection showed significantly higher NFκB activation in morphine, EcoHIV infected, and EcoHIV infected + morphine treated animals compared to placebo (Fig. 2c) , whereas day 5 post infection showed no change (Fig. 2d) . Finally, animals were gavaged with Rhodamine Dextran (Sigma) 4 h prior to Xenogen visualization on day 2 post infection, where noticeable translocation was observed especially in the EcoHIV infected + morphine treated animals (Fig. 2e) . To determine if morphine was altering this process through the mu-opioid receptor, translocation was examined using the mu-opioid receptor knock out (MORKO) mice at 2 days post-infection. No translocation was observed in the MORKO animals following morphine treatment, but surprisingly very little translocation was observed in the EcoHIV or EcoHIV + morphine groups as well (Fig. 2f) . Similarly, TLR4 knockout mice were examined, and saw a reduction in the translocation of animals treated singly with morphine or EcoHIV (Fig. 2g) . However, animals infected with EcoHIV + morphine were found to have translocation at levels similar to the wildtype genotype with the same treatment (Fig. 2g) . Overall, the induction of bacterial translocation in wild type animals infected with EcoHIV is similar to HIV-1 in humans and is abolished in MORKO and TLR4KO animals, which suggests that both genotypes play a role in the pathogenesis within the gut. Translocation was not observed in the assays performed at longer than 2 days post-infection.
Since translocation was observed, gut morphology was next examined to see if any changes were observed in treatment groups. Grossly, placebo animals had characteristic smooth and long villi while treated animals had shorter villi with inversions and perceived gaps in the epithelial cells (highlighted by black arrows, Fig. 3a) . Large intestine was similarly compared, but changes did not appear as obvious as in small intestine (Fig. 3b) . Ratios of small intestine villi length to width (Fig. 3c) and villi length to crypt depth (Fig. 3d) were measured, which showed that all three treatments had significantly lower ratios than placebo animals (p <0.05). Large intestine villi depth was measured and EcoHIV + morphine was found to be significantly decreased compared to placebo (Fig. 3e, p<0.05) . Together, the pathology of both small and large intestines is negatively impacted within EcoHIV and morphine treated animals, and especially in EcoHIV + morphine where the greatest translocation was observed, suggesting that bacterial translocation induces the changes observed via resulting inflammation.
Inflammatory pathology in the gut is likely mediated by local immune cells, so immune cell populations within the gut were investigated to see if EcoHIV with morphine caused any changes. Within CD4+ and CD8+ T-cell populations, no changes were observed in the small intestine (Fig. 4a) , cecum (Fig. 4b) , and large intestine (Fig. 4c) . In the large intestine, EcoHIV + morphine treated animals had significantly higher percentages of double positive CD4+CD8+ T-cells (p<0.05) which have been shown to be highly activated, cytokine secreting cells within the gut (Pahar et al. 2006 ). B-cell percentage, as measured by CD19, was unchanged in the small intestine (Fig. 4d) , cecum (Fig. 4e) , or large intestine (Fig. 4f) . Monocytes populations were examined in terms of CD11B+, CD11C+, or double positive populations. Similarly to T-cells, monocytes has no changes in the small intestine (Fig. 4g) or cecum (Fig. 4h ), but had a higher percentage of CD11B+CD11C+ double positive cells in the large intestine (Fig. 4i, p<0 .05), which favors inflammatory cytokines secretion when increased in ratio over CD11B+ CD11C− macrophages (Denning et al. 2007) . Supporting this environment of pro-activation in the gut, higher levels were observed among monocytes which expressed CCR5, a proinflammatory marker which also is a receptor for HIV entry into cells in gut-isolated cells as well as systemically in blood (Fig. 4j) . At the time points examined, the gross loss of CD4 cells observed in HIV do not appear to occur in EcoHIV and there is no loss of macrophages to account for bacterial translocation. However, changes in CD4+CD8+ T-cells and CD11B+ CD11C+ monocytes support a promotion of proinflammatory cytokines which has been shown to drive replication of HIV/EcoHIV.
As shown in Fig. 4 , systemic translocation of bacteria with morphine alone and EcoHIV + morphine occurred despite unchanged levels of macrophages and T cell subpopulations. Thus, functional differences were examined in the macrophages phagocytic activity. Studies have previously shown that morphine alone can cause deficiency in the phagocytic activity of macrophages (Tubaro et al. 1985; Rojavin et al. 1993; Ninković and Roy 2012) , so changes by EcoHIV and EcoHIV + morphine were examined. As compared to placebo, morphine, EcoHIV, and EcoHIV + morphine all showed a reduced uptake of FITC dextran beads indicative of compromised phagocytic ability of isolated peritoneal macrophages (Fig. 5a ). This phagocytic deficiency was verified via confocal imaging of peritoneal macrophages (Fig. 5b) .
Quantification of multiple fields showing a similar trend toward reduction in phagocytosis in the three treatment groups, however significance was not achieved (Fig. 5c ). This effect can be recapitulated in vitro using the RAW 264.7 macrophage cell line, which showed a significant reduction in all three treatment groups (Fig. 5d ) and a significant difference between EcoHIV and EcoHIV + morphine treated cells. Phagocytosis was further examined whether the observed deficiency was biased towards either gram-positive or gramnegative bacteria. Similar results were observed as with the FITC dextran beads, with both gram-positive S. aureus-opsonized particles (Fig. 5e ) and gram-negative E. coli-opsonized particles (Fig. 5f) showing diminished phagocytosis in the three treatment groups. Overall, phagocytosis is reduced by morphine and EcoHIV for either in vitro or in vivo macrophages, which may contribute to lack of bacterial clearance and sustained systemic bacteremia. The reduction in phagocytosis is universal and not selective for bacterial phenotype which stimulate TLR2 (gram positive) or TLR4 (gram negative).
Given the observed increase in systemic bacterial translocation combined with increase in activation markers and the Fig. 2 Bacterial translocation occurs early in EcoHIV infection and is exacerbated by morphine. Liver, lung, or spleen was homogenized and cultured on blood agar plates in aerobic conditions to count live CFUs. Mice were infected either 2 days (a), which showed significant translocation to liver and lung in EcoHIV+ morphine and to liver in EcoHIV, or 5 days (b), which showed no significant translocation. Homogenate from liver was tested, using RAW blue cells (Invitrogen) which express SEAP on NFκB promoter upon stimulation by PAMPs, at 2 days (c) and 5 days (d) which validated the translocation results in (a) and (b) for liver. e Mice infected for 2 days were gavaged with Rhodamine-dextran 4 h prior to Xenogen imaging. Finally, MORKO (f) or TLR4KO (g) mice were assessed for CFU growth after 2 days EcoHIV infection as above. *P<0.05 Fig. 3 Gut epithelial tight junctions and gross morphology are altered in EcoHIV infection and worsened in combination with morphine. Representative figures from distal small intestine (a) or colon (b) was stained with Hematoxylin (nuclei, brown), Alcian Blue (goblet cells and mucin, blue), and Metanil Yellow (tissue, yellow). Intact villi from small intestine sections were measured for length, width, and crypth depth. Morphine, EcoHIV, and EcoHIV + morphine showed a decrease when compared by ratios of villi length: width (e) or villi length: crypt depth (f). Colon was measured for depth (g), which is presented as an average of 6 measurements per section, and found EcoHIV + morphine to have a significantly reduced depth compared with control. Small Intestine n: Placebo, 10; Morphine, 10; EcoHIV, 16, Eco + Ms, 7. Large Intestine n: Placebo, 7; Morphine, 5; EcoHIV, 8; Eco + Ms, 5. *p<0.05, **p<0.01 lack of phagocytosis, it was hypothesized that inflammation would be apparent in systemic compartments. Indeed, at 5 days post infection a significant increase in IL-6 was observed within the liver of EcoHIV and EcoHIV + morphine treated animals, and EcoHIV + morphine animals had a significant increase over EcoHIV alone (Fig. 6a) . TNFα also showed significantly higher levels at this time point in EcoHIV infected and EcoHIV + morphine animals in liver homogenate above placebo treated animals (Fig. 6b) . Lung IL-6 levels trended to be higher but did not reach significance (Fig. 6c) whereas TNFα levels were significantly higher in EcoHIV + morphine animals and a significant increase in EcoHIV + morphine compared to EcoHIV infection alone (Fig. 6d) . Supernatant was examined from RAW 264.7 cells infected with EcoHIV as in the phagocytosis assay and found that IL-6 (Fig. 6e) and TNFα (Fig. 6f) were both significantly increased in EcoHIV infection and EcoHIV + morphine. Systemic inflammation, with elevated TNFα and IL-6 observed in the EcoHIV and morphine treated animals corroborates with observations demonstrated in HIV and IDU Fig. 4 EcoHIV with morphine does not greatly alter proportions of immune cells within the gut. Gut cells were collected from homogenized distal SI (a, d, g), Cecum (b, e, h), or colon (c, f, i) and stained for FACS analysis. CD3+ T-cells were gated and values of CD4, CD8, or CD4/CD8 double positive were examined (a, b, c), with the only significant change in DP cells being higher in morphine, EcoHIV, and EcoHIV + morphine. CD19+ B-cells were examined as a percentage of live cells (d, e, f) and no significant change was observed. CD45+ monocyte cells were gated and values of CD11B, CD11C, or CD11B/ CD11C double positive were examined (g, h, i), with the only significant change in large intestine DP cells in morphine, EcoHIV, and EcoHIV + morphine. Cells were gated for CD45+ and MHCII high to see CCR5 expression in macrophages, which saw trending increases at all locations, most notably in EcoHIV + morphine. N: Placebo, 4; morphine, 6; EcoHIV, 5; EcoHIV + Ms, 8. *p<0.05 patients. Sustained systemic Inflammation has been shown to correlate with bacterial translocation and systemic replication of EcoHIV. Morphine in conjunction with EcoHIV infection shows higher levels of inflammation in liver and lung than EcoHIV infection alone.
Finally, long-term systemic effects by EcoHIV infection were examined in the presence of morphine. In brain at 30 days post infection, EcoHIV + morphine increased expression of IL-6 (Fig. 7a) . IFNγ (Fig. 7b) and IL-1β (Fig. 7c) showed similar trends as IL-6 but did not achieve significance. Therefore, inflammation can be observed in the brain at time points well beyond 2-5 days in animals with EcoHIV + morphine.
Discussion
These results suggest that a combination of EcoHIV infection and morphine leads to an exacerbated inflammation state compared to EcoHIV infection alone, likely by influencing bacterial translocation and increasing inflammatory cytokines (Fig. 8) . Bacterial translocation from the gut has been shown to directly correlate with inflammation that drives HIV replication in long term nonprogressive HIV-infected humans despite lower amounts of LPS in their serum at levels virtually identical control patients (Brenchley et al. 2006 ). LPS as a biomarker has also been highlighted as a vital factor in what drives SIV to be pathogenic in Rhesus Macaques as compared to natural hosts who do not develop AIDS (Pandrea et al. 2008) .
Given this tight link between bacterial translocation and HIV replication, it should come as no surprise that increasing LPS further would worsen HIV pathogenesis. Previous studies have shown that morphine alone not only disrupts the physical barrier in the gut provided by epithelial cells, but also alters the function of immune cells including reducing the clearance of bacterial products by macrophages (Hilburger et al. 1997; Roy et al. 2011; Ninković and Roy 2012; Meng et al. 2013) , leading to an overt increase in the amount of systemic bacterial translocation. This effect by opioids has been suggested in limited HIV studies in heroin abusers (Ancuta et al. 2008) . While research has long suggested that HIV has a faster progression to AIDS with substance abuse, it has been difficult for epidemiological studies to validate this on a population level (Kapadia et al. 2005) . This deficiency highlights the major difficulties with studying drug abuse in a shown are representative images (b) and quantification of multiple fields (c). RAW 264.7 macrophage cell line was incubated with FITC-dextran as in part A (d). This approach was repeated with S. aureus (e) or E. coli (f) opsonized particles to examine any bias between TLR2-or TLR4-mediated phagocytosis. N: all groups = 6. *p < 0.05, **p < 0.01, ***p<0.001 human population, especially among HIV patients, and the lack of animal models to study these interactions has limited the progression to understanding the interactions between HIV and morphine. Although there have been a number of studies on effects of morphine on SIV infection in macaques (Rivera-Amill et al. 2010; Bokhari et al. 2011; Spikes et al. 2012; Rivera et al. 2013; Hollenbach et al. 2014) , to our knowledge early pathogenesis within the gut has not been investigated. In order to take advantage of genetic tools and low cost of mice, an infectious model of HIV was pursued to combine with an established model of opioid abuse to overcome these limitations in the field. Fig. 6 EcoHIV increases IL-6 and TNFα systemically, which is exacerbated by morphine. a IL-6 ELISA was performed on liver supernatant which had significantly higher levels in EcoHIV and EcoHIV + morphine treatments compared with placebo, and significantly higher levels in EcoHIV + morphine compared with EcoHIV or morphine alone. (B) TNFα in the liver showed similar results, with EcoHIV and EcoHIV + morphine having significantly higher levels than placebo, and EcoHIV + morphine having significantly higher levels than morphine alone. Lung IL-6 (c) and TNFα (d) levels were also examined, which showed EcoHIV + morphine had significantly higher levels of TNFα compared to all other groups and IL-6 trended that way but did not achieve significance. To elucidate the potential source of cytokines, supernatant from RAW264.7 cells were examined and shown to have both higher IL-6 (e) and TNFα (f) levels in EcoHIV and EcoHIV + morphine treatments. N: Placebo=4, Morphine=6, EcoHIV=6, EcoHIV + Morphine=6. *p<0.05, **p<0.01, ***p<0.001
This study showed that translocation occurred at 2 days post-infection, and EcoHIV + morphine showed the highest amount of bacterial translocation. A live CFU assay was utilized along with the RAW blue assay to account for both gram positive and gram negative bacteria, as opposed to serum LPS which only accounts for gram negative. Translocation occurred highest in the liver, which suggests the bacteria is traversing via the portal circulation. MORKO mice treated with morphine, EcoHIV, or EcoHIV + morphine showed a reduced amount of translocation at 2 days postinfection indicating that opioids, both endogenous or exogenous, likely plays a direct role in exacerbating this pathology. While endogenous opioids have not been examined directly, the stress from infection may increase endogenous opioids enough to mimic the bacterial translocation observed in exogenous opioids such as morphine. Interestingly, TLR4 knockout mice, which lack a functional receptor that recognizes LPS, also had drastically reduced translocation at 2 days post-infection. This supports the notion that LPS is playing a direct role in the pathogenesis, likely due to sustained activation in the presence of morphine (Banerjee et al. 2013) . However, TLR4 is not the only player in this process. EcoHIV + morphine had translocation similarly to wildtype animals, which likely reflects an abundance of stress on gut homeostasis even in the absence of TLR4. TLR2 has also been shown to be increased by morphine alone and in the presence of HIV proteins (El-Hage et al. 2011; Kwok et al. 2012; Meng et al. 2013) , and very likely plays a role in the bacterial translocation observed.
The clearance of bacteria from systemic compartments observed contrasts from HIV and SIV, where LPS is observed in all stages of uncontrolled infection including early, late, and AIDS phases (Brenchley et al. 2006; Estes et al. 2010; Nowroozalizadeh et al. 2010) . Gut CD4 loss has been suggested to contribute to microbial translocation in SIV (Brenchley et al. 2008 ), which was not observed at the time points examined in this model and could be a reason for this conflict. Given that this model allows us to look at very early Fig. 7 Long term (30 day) EcoHIV infection combined with morphine increases cytokine expression in brain over infection alone. RNA was isolated from brain and analyzed via qPCR for IL-6 (a), . N: Placebo = 3, Morphine = 5, EcoHIV = 3, EcoHIV + morphine=5. *p<0.05 Fig. 8 Model of EcoHIV and morphine induced bacterial translocation. Bacterial translocation is induced likely by a combination of morphine altering tight junction expression and EcoHIV activating an inflammatory response. (1) Bacteria is able to translocate across the epithelial barrier which alters gut morphology (2), likely by activating basolateral TLRs, (3) Phagocytosis of bacteria by macrophages is diminished, which allows the spread of bacteria systemically to tissues such as liver. (4) Continued inflammation was observed in both liver and brain tissues, despite the clearance of translocated bacteria. This may result from prolonged TLR4 activation, as TLR4KO mice had decreased translocation in this study. TLR4 typically undergoes tolerance following activation however this has been shown to be disrupted with morphine leading to long term activation (Banerjee et al. 2013) stages of disease, EcoHIV is beneficial for studying the mechanisms of early HIV pathogenesis of HIV in the context of drugs of abuse, which has been nearly impossible to study due to the unknown infection status of individuals. This model may also give a resolution to mechanisms at early time points which have been unable to be studied in HIV. Future studies will examine the gut associated lymphoid tissue (GALT) to understand if EcoHIV infection can disrupt functional immunity at later time points as is observed in HIV and SIV.
Unexpectedly, bacterial translocation was not observed at 5 days post-infection. One explanation is that systemic translocation may be prevented at this point by a recovery of the GALT. While a decrease in phagocytosis was observed at this time point of infection in primary macrophages ex vivo, the microenvironment in vivo may support a greater clearance of bacteria preventing its translocation to the liver and other systemic tissues. Additionally, other normal gut homeostasis mechanisms such as the increase of mucin or defensin secretion, which would protect the epithelial barrier, may be increased due to inflammation (Clark and Coopersmith 2007) . Both mechanisms need be examined in future studies to elucidate how they change given exposure to morphine and EcoHIV infection.
Despite the lack of detectable bacterial translocation at this time point, pathology and inflammation were both still apparent which suggests that the translocation had a persistent effect and could play a role in HIV pathogenesis even after if cleared. However, timepoints this early in HIV pathogenesis have not been examined which could account for the difference and it is unknown whether disruption of gut homeostasis at early stages happens stably or in phases with the ongoing pathogensis of HIV.
In addition to pathology in the gut, this study showed that EcoHIV and morphine have a negative effect on the ability of peritoneal macrophages to perform phagocytosis, which plays a major role in the clearance of translocated bacteria. This coincides with previous data that showed morphine alone causes a deficiency in phagocytosis (Tubaro et al. 1985; Casellas et al. 1991; Rojavin et al. 1993; Ninković and Roy 2012) . A breech in epithelial barrier is not enough for translocation to become systemic, so a decrease in phagocytosis likely contributes to the bacterial translocation observed to liver.
One major difference between this model and HIV pathogenesis is the lack of early CD4+ T-cell depletion within the gut which have been observed at acute stages of HIV infection (Brenchley et al. 2004; Gordon et al. 2010) . Prolonged time points in this model are needed to resolve this difference, as this study included time points that were very early relative to what has been examined in HIV or SIV studies. Thus, this model provides flexibility to study time points which are unattainable or impractical to study in HIV or SIV infections. Examining CD4 cells at a deeper resolution, depletion of Th17 cells have been suggested to be the predominant cause for the observed microbial translocation following SIV infection in Rhesus Macaques since Th17 cell depletion is not observed in nonprogressors (Brenchley et al. 2008) . Recent data from our lab suggests that morphine alone can induce a deficiency in the Th17 response (communicated), which supports the results in this study. Future work will examine the effect of morphine on CD4 skewing in EcoHIV infection with an emphasis on the role of Th17 cell depletion and microbial translocation.
Despite clearance of bacteria, cytokines TNFα and IL-6 were observed at high levels in EcoHIV treated animals in combination with morphine in both liver and lung at day 5 post-infection. This inflammation can act to drive systemic HIV replication and drive HIV into long-lived cellular reservoirs such as macrophages, where it can continue promoting secretion of inflammatory molecules in the absence of further translocation. HIVand opioid abuse have been shown to cause more severe neurocognitive deficits due to immune dysfunction (Hauser et al. 2007; Hollenbach et al. 2014) , so morphine treatment with EcoHIV was investigated for altered inflammation in the brain. Indeed, higher expression of inflammatory cytokines was observed in brains of EcoHIV infected mice in combination with morphine 30 days post-infection consistent with inflammation playing a significant role in long-term neurocognitive defects. While neurocognitive defects are commonly observed in IDU HIV patients, it is impossible to study the direct effects of opioids and how they contribute to neurological symptoms in people. Comorbidities in human IDU, such as nutritional deficiencies, stress, or lack of medical care, make an animal model to study the mechanism leading to neurocognitive defects extremely desirable. HIV patients who abuse substances have much lower adherence to medications so, despite reasonable therapeutics being available, they are more susceptible to negative consequences of uncontrolled infection (Hinkin et al. 2004) . EcoHIV as an animal model provides a great opportunity to study HIV with drugs of abuse in combination with antiretroviral therapies to finally tease apart the mechanisms of substance abuse with the comorbidities associated with aberrant lifestyles. Future work with EcoHIV will examine whether the inflammation observed in the brain is instigated by the original translocation events observed or is an independent event induced by morphine and EcoHIV infection.
Overall, despite some limitations, EcoHIV in combination with morphine is a model for early pathogenesis of HIV which recapitulates pathology observed HIV patients such as induction of bacterial translocation, gut pathology, and inflammation. As this study was concerned with HIVand how infection influences gut homeostasis, including immune and epithelial cells, EcoHIV provides a major advantage over humanized mice where crosstalk between cells from human and mice may be compromised. While the entry into cells by EcoHIV differs from HIV infection (MCAT-1 versus CD4/co-receptors), all HIV proteins are present aside from gp120. Though gp120 may contribute to pathology, we believe that this murine model of HIV offers the best compromise to study the gut as a system between humanized mice infected with HIVand transgenic mice expressing HIV proteins.
The experimental design of this study examined a very early time point of HIV pathogenesis that has not been examined with other models. For instance it is not known how early translocation occurs in HIV infection, and once established whether it is constant or occurs in cycles. Any differences between the present work and other studies may be resolved with experimental manipulation such as utilizing different lengths of EcoHIV infection.
This model is particularly useful for studying the interactions of opioids with HIV as it provides flexibility for looking at different opioid paradigms in relation to HIV infection, in addition to having the ability to utilize different genetic backgrounds such as MORKO mice which are not available when using humanized mice. The present study pretreated animals with a slow release morphine pellet that limits the mice exposure to withdrawal effects. Shifting the treatment to different dosing patterns of morphine such as giving morphine after EcoHIV infection rather than before or using an opioid dosing paradigm which includes withdrawal may better reflect human exposure to drugs in HIV infection, however this needs to be optimized in future studies.
Given the results presented, EcoHIV provides a useful avenue for studying HIV and drugs of abuse where other models have fallen short. Future studies will also investigate whether changes in microbiota within the gut can contribute to translocation, which was not addressed in this study. This model can be used to elucidate the mechanisms underlying the interactions between HIV and drugs of abuse at early stages of disease.
